

Entrepreneurial ID «venture leaders» 2009



Name: Clement
Contact: Virginie.clement@medecine.unige.ch
University / School (if applicable): University of Geneva- University Hospital of Geneva
Project/ Company name: Stemergie

Web site: www.stemergie.com



Short description: Stemergie provides an innovative direct and non-toxic technology to develop niche buster drugs against cancer-initiating cells from human tumors

Industry: bio-tech

The venture leader

Education and Degrees

Until present: "Maitre-Assistante" and Preclinical tutor
2007: Post-doctoral position in cancer stem cell and developmental signaling pathways.
2005: Ph.D in Biology

Entrepreneurial Profile

As my collaborator, Ivan Radovanovic MD.PhD, is a full-time neurosurgeon, I am partially in charge of running the laboratory on a daily basis, and I am therefore considered as a nodal point for the lab and project leader for Stemergie. My entrepreneurial personality is highly stimulated by the possibility of being involved in scientific communications, supervising people and coordinating highly productive and interactive collaborative projects in Switzerland. I therefore assume an independent coordinator position at the crossroad of fundamental biology, medicine and managing. Dynamic, ambitious, organized and communicative, I strongly believe to have the skills and the motivations required for initiating Stemergie's business venture. As a scientist working in translational research, I am confronted to the reality of patients and to the biological aspects of the disease, which in turns helped me to reconsider our skills on cancer and our way of developing therapeutic strategies. I can therefore guarantee that beyond a revolution, which would simply be utopic, Stemergie has the potential to find his own niche in the cancer stem cell field in order to quickly generate a stream of revenues.

The Company / project


Problem

In 2008, 1.4 millions of Americans were diagnosed for cancer. At its origin, cancer stem cells which is likely to represent the resistance to treatment, recurrence and metastasis of the tumor. If we want to eradicate cancer, this nasty population of cancer stem cells should be our enemy number, the one to target and to eliminate.

Solution

Stemergie provides an innovative direct and non-toxic technology to propagate, identify and purify cancer-initiating cells (CICs) from human tumors, including cancers of the central and peripheral nervous system and metastasis to the brain. Stemergie is intended to pharmaceutical companies, Biotech, Hospitals and Research Institutes and provides the right tool the expertise in cancer stem cells to validate efficient and reliable anti-cancer stem cell agents.

Product and services



In vitro and in vivo screening:

Stemergie is a technology allowing the validation of drugs, vaccines, diagnostic tools. An in vitro and in vivo protocols for screening and testing anti-cancer stem cell compounds were designed and protected.



Cancer Stem Cell Biobank. Based on Stemergie's technology, we can provide long term cultures of primary cancer stem cell strains. At present, our collection is unique and already contains more than 10 specimens.

CSC and Marker	Stemergie
Antibody (100CHF/ analyse)	No Antibody (0 CHF/ analyse)
Time: 2h	Time: 10 min
Special FACS Machine	Any FACS Machine
Short term culture (5 weeks)	Long term culture (2 years)
Conflicting results Efficiency <50%	Reproducible results Efficiency ~95%

Though not yet incorporated, Stemergie should be created by Q1 2010, the service platform should be functional by QIII 2010, and the first sales plan for 2011. Ideally, we estimate our financial needs to ~1'000'000 CHF for the next 3 years (1 employee, setting up the biobank and service platform, initiation of R&D activities). We are looking for financing and/or partners specialized in developing small molecules chemistry, immunology and diagnostic tools.